The 2nd U.S. Circuit Court of Appeals' ruling that truthful communications between a physician and a drug company representative are protected speech under the First Amendment is a victory for patients, PhRMA General Counsel Mit Spears writes. Using drugs in ways that the FDA has not approved is valuable and even can be the standard of care. Ensuring timely and robust communications between health care professionals and biopharmaceutical firms is important as the focus increases on using the best possible therapies and controlling costs.
Published in Brief: